Louis, MO 63132, USA; ddenardo{at}wustl.edu Results In KPC mice, the expression levels of phosphorylated STAT3 (pSTAT3) were increased in PDAC cells as they progressed on FAK inhibitor therapy. This ...

General and administrative expense for the year ended December 31, 2024 increased to $4.7 million, compared to $4.2 million for the year ended December 31, 2023 primarily due to increased salaries and ...

Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio ...

Currently, ERK inhibitors such as JSI-1187-01, ASN007, and KO-947 are in Phase I clinical trials; ClinicalTrials.gov Identifier: NCT04418167, NCT03415126, and NCT03051035, respectively. Janus ...

The invention also includes delivery mechanisms to enhance the bioavailability and efficacy of the inhibitors. EGFR, RAF1, and STAT3 Inhibitors Patent WO 2024160878 A1: This patent focuses on ...

inhibitors, and STAT3 inhibitors as key weapons in the fight against cancer. As Moleculin Biotech advances its drug candidates through clinical trials, it holds the promise of bringing novel cancer ...

Session Date and Time: Monday, April 28, 2:00 - 5:00 p.m.

A drug typically prescribed for arthritis halts brain-damaging seizures in mice that have a condition like epilepsy, ...

IL-23R Inhibitor Peptide-1 可特异性结合 IL-23R，阻断 IL-23 与 IL-23R 的结合，从而抑制 IL-23R 介导的信号转导通路。例如，能阻止 IL-23 诱导的 STAT3 磷酸化，STAT3 是细胞内重要信号转导分子，其磷酸化被抑制后，相关基因表达受影响，细胞炎症因子分泌减少，进而抑制 ...